References
- Pankey GA. Tigecycline. J Antimicrob Chemother 2005; 56:470–80.
- Meagher AK, Ambrose PG, Grasela TH, Ellis-Grosse EJ. The pharmacokinetic and pharmacodynamic profile of tigecycline. Clin Infect Dis 2005;41(Suppl 5):S333–40.
- Rodvold KA, Gotfried MH, Cwik M, Korth-Bradley JM, Dukart G, Ellis-Grosse EJ. Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. J Antimicrob Chemother 2006;58:1221–9.
- Muralidharan G, Micalizzi M, Speth J, Raible D, Troy S. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob Agents Chemother 2005; 49:220–9.
- Tombs NL. Tissue distribution of GAR-936, a broad-spectrum antibiotic, in male rats. Abstract 413. Programs and Abstracts of the Thirty-ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1999. Washington, DC:American Society of Microbiology; 1999. p. 302.
- Ray L, Levasseur K, Nicolau DP, Scheetz MH. Cerebral spinal fluid penetration of tigecycline in a patient with Acinetobacter baumannii cerebritis. Ann Pharmacother 2010;44:582–6.
- European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 2.0, 1 January 2012 to 31 December 2012; 2012. Available at: http://www.eucast.org/clinical_breakpoints/ (accessed 10 December 2012).
- Dandache P, Nicolau DP, Sakoulas G. Tigecycline for the treatment of multidrug-resistant Klebsiella pneumoniae meningitis. Infect Dis Clin Pract 2009;17:66–8.